309 related articles for article (PubMed ID: 31356481)
1. Circulating Anti-cytolethal Distending Toxin B and Anti-vinculin Antibodies as Biomarkers in Community and Healthcare Populations With Functional Dyspepsia and Irritable Bowel Syndrome.
Talley NJ; Holtmann G; Walker MM; Burns G; Potter M; Shah A; Jones M; Koloski NA; Keely S
Clin Transl Gastroenterol; 2019 Jul; 10(7):e00064. PubMed ID: 31356481
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome.
Rezaie A; Park SC; Morales W; Marsh E; Lembo A; Kim JH; Weitsman S; Chua KS; Barlow GM; Pimentel M
Dig Dis Sci; 2017 Jun; 62(6):1480-1485. PubMed ID: 28451914
[TBL] [Abstract][Full Text] [Related]
3. Gut microbiota profiles and the role of anti-CdtB and anti-vinculin antibodies in patients with functional gastrointestinal disorders (FGID).
Vasapolli R; Schulz C; Schweden M; Casèn C; Kirubakaran GT; Kirste KH; Macke L; Link A; Schütte K; Malfertheiner P
Eur J Clin Invest; 2021 Dec; 51(12):e13666. PubMed ID: 34390492
[TBL] [Abstract][Full Text] [Related]
4. Second-Generation Biomarker Testing for Irritable Bowel Syndrome Using Plasma Anti-CdtB and Anti-Vinculin Levels.
Morales W; Rezaie A; Barlow G; Pimentel M
Dig Dis Sci; 2019 Nov; 64(11):3115-3121. PubMed ID: 31152332
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects.
Pimentel M; Morales W; Rezaie A; Marsh E; Lembo A; Mirocha J; Leffler DA; Marsh Z; Weitsman S; Chua KS; Barlow GM; Bortey E; Forbes W; Yu A; Chang C
PLoS One; 2015; 10(5):e0126438. PubMed ID: 25970536
[TBL] [Abstract][Full Text] [Related]
6. Study of Antibodies to Cytolethal Distending Toxin B (CdtB) and Antibodies to Vinculin in Patients with Irritable Bowel Syndrome.
Zaki MES; Elhammady D; Foda Salama M; Abdelsalam M; Osman AOB
F1000Res; 2021; 10():303. PubMed ID: 34754418
[No Abstract] [Full Text] [Related]
7. Immunization with cytolethal distending toxin B produces autoantibodies to vinculin and small bowel bacterial changes in a rat model of postinfectious irritable bowel syndrome.
Morales W; Triantafyllou K; Parodi G; Weitsman S; Park SC; Rezaie A; Pichetshote N; Lin E; Pimentel M
Neurogastroenterol Motil; 2020 Oct; 32(10):e13875. PubMed ID: 32436301
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with the use of anti-CdtB and anti-vinculin antibodies in patients with diarrhea in Mexico.
Schmulson M; Balbuena R; Corona de Law C
Rev Gastroenterol Mex; 2016; 81(4):236-239. PubMed ID: 27681080
[TBL] [Abstract][Full Text] [Related]
9. Autoimmunity Links Vinculin to the Pathophysiology of Chronic Functional Bowel Changes Following Campylobacter jejuni Infection in a Rat Model.
Pimentel M; Morales W; Pokkunuri V; Brikos C; Kim SM; Kim SE; Triantafyllou K; Weitsman S; Marsh Z; Marsh E; Chua KS; Srinivasan S; Barlow GM; Chang C
Dig Dis Sci; 2015 May; 60(5):1195-205. PubMed ID: 25424202
[TBL] [Abstract][Full Text] [Related]
10. Cytolethal distending toxin B inoculation leads to distinct gut microtypes and IBS-D-like microRNA-mediated gene expression changes in a rodent model.
Leite G; de Freitas Germano J; Morales W; Weitsman S; Barlow GM; Parodi G; Pimentel ML; Villanueva-Millan MJ; Sanchez M; Ayyad S; Rezaie A; Mathur R; Pimentel M
Gut Microbes; 2024; 16(1):2293170. PubMed ID: 38108386
[TBL] [Abstract][Full Text] [Related]
11. Gender difference in the overlap of irritable bowel syndrome and functional dyspepsia: a prospective nationwide multicenter study in Korea.
Nam K; Kim N; Song HJ; Baik GH; Choi SC; Kim HJ; Lee JY; Park KS; Park SY; Park SJ
J Gastroenterol; 2021 Jun; 56(6):537-546. PubMed ID: 33687537
[TBL] [Abstract][Full Text] [Related]
12. Classification of pediatric functional gastrointestinal disorders related to abdominal pain using Rome III vs. Rome IV criterions.
Edwards T; Friesen C; Schurman JV
BMC Gastroenterol; 2018 Mar; 18(1):41. PubMed ID: 29549882
[TBL] [Abstract][Full Text] [Related]
13. No difference in serum levels of B-cell activating receptor and antibodies against cytolethal distending toxin B and flagellin in post-infectious irritable bowel syndrome and chronic fatigue syndrome after
Hanevik K; Saghaug C; Aaland M; Morch K; Langeland N
JGH Open; 2022 Mar; 6(3):185-188. PubMed ID: 35355666
[TBL] [Abstract][Full Text] [Related]
14. The clinical overlap between functional dyspepsia and irritable bowel syndrome based on Rome III criteria.
Wang A; Liao X; Xiong L; Peng S; Xiao Y; Liu S; Hu P; Chen M
BMC Gastroenterol; 2008 Sep; 8():43. PubMed ID: 18808723
[TBL] [Abstract][Full Text] [Related]
15. Impact of coexisting irritable bowel syndrome and non-erosive reflux disease on postprandial abdominal fullness and sleep disorders in functional dyspepsia.
Futagami S; Yamawaki H; Shimpuku M; Izumi N; Wakabayashi T; Kodaka Y; Nagoya H; Shindo T; Kawagoe T; Sakamoto C
J Nippon Med Sch; 2013; 80(5):362-70. PubMed ID: 24189354
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia.
Hammer J; Eslick GD; Howell SC; Altiparmak E; Talley NJ
Gut; 2004 May; 53(5):666-72. PubMed ID: 15082584
[TBL] [Abstract][Full Text] [Related]
17. Comparison of pancreatic enzyme abnormalities and protease-activated receptor-2-positive eosinophils in the duodenum of patients with functional dyspepsia-irritable bowel syndrome overlap with functional dyspepsia alone in Asian populations.
Futagami S; Kessoku T; Kasai Y; Higurashi T; Nakajima A; Agawa S; Yamawaki H; Nakamura K; Habiro M; Kawawa R; Ueki N; Higashida S; Watanabe Y; Yamato H; Yamamoto T; Takasaki Y; Ito K; Hojo M; Isayama H; Motoda N; Ohashi R; Siah KTH; Ng CK; Gwee KA
J Gastroenterol Hepatol; 2023 Oct; 38(10):1778-1786. PubMed ID: 37278449
[TBL] [Abstract][Full Text] [Related]
18. Overlap between irritable bowel syndrome and functional dyspepsia including subtype analyses.
Choi YJ; Kim N; Yoon H; Shin CM; Park YS; Kim JW; Kim YS; Lee DH; Jung HC
J Gastroenterol Hepatol; 2017 Sep; 32(9):1553-1561. PubMed ID: 28160607
[TBL] [Abstract][Full Text] [Related]
19. Overlap of Irritable Bowel Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors.
von Wulffen M; Talley NJ; Hammer J; McMaster J; Rich G; Shah A; Koloski N; Kendall BJ; Jones M; Holtmann G
Dig Dis Sci; 2019 Feb; 64(2):480-486. PubMed ID: 30368683
[TBL] [Abstract][Full Text] [Related]
20. [A correlation study between diarrhea-predominant irritable bowel syndrome complicated functional dyspepsia patients of Gan-stagnation Pi-deficiency syndrome and gastrointestinal hormones].
Zhao L; Song W; Zhu P; Zhang Y; Bu P
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Oct; 34(10):1168-72. PubMed ID: 25509256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
